期刊文献+

氟尿嘧啶(5-FU)及亚叶酸钙(LV)联合奥沙利铂治疗胃癌26例的临床观察

Fluorouracil (5 -FU) and Leucovorin (LV) oxaliplatin in the treatment of clinical observation of 26 cases of gastric cancer
下载PDF
导出
摘要 目的:观察奥沙利铂(L—OPH)联合氟尿嘧啶(5-FU)及亚叶酸钙(LV)治疗术后胃癌的疗效和不良反应。方法:26例胃癌术后患者,采用奥沙利铂(L—OPH)联合氟尿嘧啶(5-FU)及亚叶酸钙(LV)方案治疗,每月重复1次,治疗3个周期后评价疗效。结果:26例患者中,完全缓解3例(11.5%),部分缓解18例(69.2%),近期有效率80.8%。主要不良反应为恶心、乏力、感觉神经毒性和腹泻,无化疗相关死亡。结论:奥沙利铂(L—OPH)联合氟尿嘧啶(5-FU)及亚叶酸钙(LV)方案治疗胃癌疗效显著,安全性高,不良反应经处理后均可耐受,无严重不良反应发生,可作为一种供选择方案。 Goal: After observes Austria Sha Libo the (L - OPH) union fluorine uracil (5 - FU) and the Asi- an folic acid calcium (LV) iatrotechnics the stomach cancer curative effect and responded not good. Method: 26 example stomach cancer technique future trouble, uses Austria Sha Libo the (L -OPH) union fluorine uracil (5 - FU) and the Asian folic acid calcium (LV) plan treatment, each month duplicates 1 time, after treats for 3 cycles to appraise the curative effect. Finally: In 26 example patients, alleviates 3 examples completely (11.5%), the part alleviates 18 examples (69.2%), in the near future effectiveness 80.8%. Mainly not good responded for disgusting, asthenia, sensory nerve toxicity and diarrhea, does not have the chemotherapy correlation death. Conclu- sion: Austria Sha Libo the (L -OPH) union fluorine uracil (5 -FU) and the Asian folic acid calcium (LV) plan treats the stomach cancer curative effect to be remarkable, the security is high, responded not good may endure after processing, not serious responds the occurrence not good, may take one kind supplies the choice plan.
作者 付朝江
出处 《健康天地(学术版)》 2009年第12期110-111,共2页
关键词 奥沙利铂 氟尿嘧啶 亚叶酸钙 胃癌 联合化疗 Oxaliplatin fluorouracil Leucovorin gastric cancer combination chemotherapy
  • 相关文献

参考文献7

  • 1Folprecht G. Kohne CH, The role of new agengts in the treatment of colorectal caner, Oncolo gy, 2004,66 (1); 1-17.
  • 2应杰儿,钟海均,冯海洋.FOLFOX4方案治疗晚期大肠癌的临床观察[J].肿瘤防治杂志,2005,12(18):1423-1424. 被引量:28
  • 3Aimed FE. Molecular markers that predict response colon cancer therapy. Expert Rev Mol Diagn, 2005,5 (3) :353 -375.
  • 4Folprecht G. Kohne CH, The role of new agengts in the treatment of colorectal caner, Oncolo gy, 2004,66 (1):1-17.
  • 5卓越.新编临床药物买用手册[M].北京:科学出版社,2004:256-266.
  • 6Raymond E, Faivre S Chaney S, eta. I Cellular and molecularpharmacology of oxaliplatin[J].MolCancerTher, 2002, 1 (3) :227 -235.
  • 7林万隆,陈强.奥沙利铂的药理作用及临床应用[J].中国肿瘤临床,2000,27(11):872-874. 被引量:333

二级参考文献12

  • 1张文,许立功.晚期结直肠癌的化疗进展[J].中国癌症杂志,2004,14(4):378-382. 被引量:25
  • 2陆仰东.国产奥沙利铂为主的联合化疗治疗51例晚期大肠癌疗效观察[J].中国肿瘤临床,2004,31(24):1401-1403. 被引量:5
  • 3Li X M,Arch Toxicol,1998年,72卷,9期,574页
  • 4Goldstein D, Mitchell P, Michal M, et al. Australian experience of a modified schedule of FOLFOX with high activity and tolerability and improved convenience in untreated metastatic colorectal cancer Patients[J]. Br J Cancer,2005, 92(5) :832-837.
  • 5Hsuen Lim E, Seng Cheong Lim R, Seng Wu T, et al. Oxaliplatin/fluorouracil/leucovorin in advanced colorectal carcinoma:an asian experience[J]. Pann Pharmacother,2003,37(12) :1909-1912.
  • 6Kemeny N, Garay C A, Gurtler J, et al. Randomized multicenter phase Ⅱ trial of bolus plus in FU sional fluorouracil/leucovorin compared with fluorouracil/leucovorin plus oxaliplatin as third-line treatment of patients with advanced colorectal cancer [J]. J Clin Oncol,2005,23(1) :248-252.
  • 7Parkin D M, Bray F, Ferlay J, et al. Global cancer statistics,2002[J]. CA Cancer J Clin, 2005, 55(2) :74-108.
  • 8Rixe O, Ortuzar W,Alvarez M, et al. Oxaliplatin,tetraplatin, cisplatin, and carboplatin: spectrum of activity in drug resistant celllines and in the cell lines of the National Cancer Institute ' s Anticancer Drug Screen panel[J]. Biochem Pharmacol, 1996,52 (12): 1855 -1865.
  • 9Kuebler J P,de Gramont A. Recent Experience With Oxaliplatin or lrinotecan combined with 5-fluorouracil and leucovorin in the treatment of colorectal cancer[J]. Semin Oncol,2004,30(4 Suppl 15) :40-47.
  • 10Simpson D, Dunn C, Curran M. Oxaliplatin: a review of its use in combination therapy for advanced metastatic colorectal cancer [J]. Drugs, 2003,63(19) :2127-2156.

共引文献354

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部